Search results for "Angiotensin"

In vivo angiotensin I-converting enzyme inhibition by long-term intake of antihypertensive lactoferrin hydrolysate in spontaneously hypertensive rats

2013

Abstract We evaluated the effect of the long-term intake of a bovine lactoferrin hydrolysate enriched in low molecular weight peptides (LFH  in vivo mechanism of action. Male spontaneously hypertensive rats received tap water (negative control), captopril (positive control, 76 mg/kg/day), LFH  in vivo mechanism for the antihypertensive effect of long-term oral administration of LFH

Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas

2013

Key points • Two distinct angiotensin-(1–7) [Ang-(1–7)] receptor blockers, A779 and d-Pro-Ang-(1–7), can completely prevent Ang-(1–7)-induced vasorelaxation. • Genetic deficiency of Mas completely prevents vascular responses to Ang-(1–7). • Genetic deficiency of Mas completely prevents vascular responses to other NO-dependent vasorelaxants (bradykinin). • Mas plays a key role in NO-mediated vasodilatation by modulating vasorelaxant-mediated phosphorylation of endothelial nitric oxide synthase in endothelial cells. Abstract  The heptapeptide angiotensin-(1–7) is a biologically active metabolite of angiotensin II, the predominant peptide of the renin–angiotensin system. Recently, we have show…

Polymorphisms of the renin-angiotensin genes and the outcome of BP and microalbuminuria in essential hypertension: a prospective three years follow-u…

1999

CRT-723 Is the Sporadic Thoracic Aortic Aneurysm the Result of an Inflammatory Process?

2014

Sporadic thoracic aortic aneurysm (S-TAA) is potentially devastating with severe morbidity and mortality. The histopathologic underlying abnormality of both ascending aortic aneurysm and dissection is medial degeneration, a pathological entity initially described as no inflammatory lesions of smooth

A-6G polymorphism of the angiotensinogen gene and body weight changes in essential hypertension: a prospective study

2001

Platelet Activity in Relation to Smoke and Exercise in Patients with Chronic Obstructive Lung Disease: Effects of Platelet Antiaggregating Drugs

1984

Lung tissue is involved in the synthesis and/or metabolism of many vasoactive substances such as histamine, serotonin, dopamine, norepinephrine, bradikinin, angiotensin II and prostaglandins (1).

Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling

2015

Cardiac hypertrophy accompanies many forms of heart disease, including ischemic disease, hypertension, heart failure, and valvular disease, and it is a strong predictor of increased cardiovascular morbidity and mortality. Deletion of bone marrow kinase in chromosome X (Bmx), an arterial nonreceptor tyrosine kinase, has been shown to inhibit cardiac hypertrophy in mice. This finding raised the possibility of therapeutic use of Bmx tyrosine kinase inhibitors, which we have addressed here by analyzing cardiac hypertrophy in gene-targeted mice deficient in Bmx tyrosine kinase activity. We found that angiotensin II (Ang II)-induced cardiac hypertrophy is significantly reduced in mice deficient i…

Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection

2020

To determine the effect renin-angiotensin system blockers on the outcome in patients with hypertension and concurrent COVID-19 infection, we searched PubMed, the Cochrane Library, and Google Scholar for relevant articles. Twelve studies with a total of 16,101 patients met the inclusion criteria. The mortality rate among the users of angiotensin converting enzyme inhibitors or angiotensin receptor blockers was 12.15% and in non-users it was 14.56% (risk ratio 0.70, 95% CI [0.53-0.91], P < 0.007). There was no difference in the risk of death between the use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers (risk ratio 1.09, 95% CI [0.90 -1.32]). We conclude tha…

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

2015

Current therapy directed at delaying the progression of diabetic nephropathy includes intensive glycemic and optimal blood pressure control, renin angiotensin-aldosterone system blockade and multifactorial intervention. However, the renal protection provided by these therapeutic modalities is incomplete. There is a scarcity of studies analysing the nephroprotective effect of antihyperglycaemic drugs beyond their glucose lowering effect and improved glycaemic control on the prevention and progression of diabetic nephropathy. This article analyzes the exisiting data about older and newer drugs as well as the mechanisms associated with hypoglycemic drugs, apart from their well known blood gluc…

Zur Frage der renalen Steuerung der Z. glomerulosa der NNR

1963

An weiblichen Ratten wird die Aktivitatslage der Z. glomerulosa und fasciculata nach Ausschaltung der Reninproduktion durch Nephrektomie unter verschiedenen experimentellen Bedingungen untersucht.